Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
August 02 2024 - 7:00AM
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical
company focused on delivering novel therapeutics for nonalcoholic
steatohepatitis (NASH), today announced the appointment of Shannon
Kelley as General Counsel, effective August 5, 2024.
Bill Sibold, Chief Executive Officer of Madrigal, stated,
“Shannon is an outstanding leader who brings a wealth of expertise
to her new role as General Counsel. She joined the Madrigal team in
2024 as Chief Compliance Officer and played an instrumental role
guiding the company through a period of rapid growth. I feel
privileged to be working with Shannon and the other members of our
leadership team as we build the foundation for Madrigal’s
future.”
Ms. Kelley has more than 20 years of diverse healthcare
experience as a legal and compliance professional. She joined
Madrigal from Sanofi, where she served in roles of increasing
responsibility. She was most recently Chief Compliance Officer,
North America and Global Specialty Care, responsible for compliance
across all therapeutic areas. Prior to Sanofi, Ms. Kelley was
Global Compliance and Commercial Legal Counsel for Boston
Scientific Corporation. Earlier in her career, she spent ten years
in enforcement roles with the U.S. Federal Government. Ms. Kelley
was a Trial Attorney for the Department of Justice in Washington,
D.C. and an Assistant United States Attorney and Deputy Chief of
Litigation for the U.S. Attorney’s Office for the District of
Massachusetts focused on healthcare matters. Ms. Kelley earned her
J.D. from American University Law School and holds a B.S. degree
from Georgetown University in Foreign Service.
Ms. Kelley stated, “At Madrigal, we have a unique opportunity to
deliver a groundbreaking therapy to patients living with NASH, the
leading cause of liver transplantation in women in the U.S. and the
second leading cause for all liver transplantation. Our goal is to
build a great company that will be an industry leader for years to
come, and I look forward to being a strategic partner to the
leadership team and continuing to build a strong culture of ethics
and integrity.”
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), a liver disease with high
unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom),
is a once-daily, oral, liver-directed THR-β agonist designed to
target key underlying causes of NASH. For more information, visit
www.madrigalpharma.com.
Investor Contact Tina Ventura,
IR@madrigalpharma.com
Media ContactChristopher Frates,
media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Sep 2023 to Sep 2024